203 related articles for article (PubMed ID: 18473851)
1. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.
Zhou SF
Curr Pharm Des; 2008; 14(10):990-1000. PubMed ID: 18473851
[TBL] [Abstract][Full Text] [Related]
2. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
Zhou SF; Xue CC; Yu XQ; Li C; Wang G
Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
[TBL] [Abstract][Full Text] [Related]
3. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.
Zhou S; Chan E; Li X; Huang M
Ther Clin Risk Manag; 2005 Mar; 1(1):3-13. PubMed ID: 18360537
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
7. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
Potęga A; Fedejko-Kap B; Mazerska Z
Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
[TBL] [Abstract][Full Text] [Related]
8. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.
Sevrioukova IF; Poulos TL
Curr Top Med Chem; 2014; 14(11):1348-55. PubMed ID: 24805065
[TBL] [Abstract][Full Text] [Related]
9. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
Foti RS; Rock DA; Pearson JT; Wahlstrom JL; Wienkers LC
Drug Metab Dispos; 2011 Jul; 39(7):1188-95. PubMed ID: 21447734
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Filppula AM; Mustonen TM; Backman JT
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):739-748. PubMed ID: 29956478
[TBL] [Abstract][Full Text] [Related]
12. Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6',7'-Dihydroxybergamottin.
Sevrioukova IF
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480231
[TBL] [Abstract][Full Text] [Related]
13. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
[TBL] [Abstract][Full Text] [Related]
14. Effect of Chinese herbs on CYP3A4 activity and expression in vitro.
Lau C; Mooiman KD; Maas-Bakker RF; Beijnen JH; Schellens JH; Meijerman I
J Ethnopharmacol; 2013 Sep; 149(2):543-9. PubMed ID: 23876595
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds.
Bolles AK; Fujiwara R; Briggs ED; Nomeir AA; Furge LL
Drug Metab Dispos; 2014 Dec; 42(12):2087-96. PubMed ID: 25273356
[TBL] [Abstract][Full Text] [Related]
16. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4.
Tang LWT; Teng JW; Verma RK; Koh SK; Zhou L; Go ML; Fan H; Chan ECY
Drug Metab Dispos; 2021 Sep; 49(9):856-868. PubMed ID: 34326139
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Evaluation of Cytochrome P450 3A4 Inhibition and Hepatotoxicity in HepaRG 3-D Spheroids.
Shin DS; Seo H; Yang JY; Joo J; Im SH; Kim SS; Kim SK; Bae MA
Int J Toxicol; 2018; 37(5):393-403. PubMed ID: 29923436
[TBL] [Abstract][Full Text] [Related]
18. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
19. Development of In Silico Models for Predicting Potential Time-Dependent Inhibitors of Cytochrome P450 3A4.
Xu M; Lu Z; Wu Z; Gui M; Liu G; Tang Y; Li W
Mol Pharm; 2023 Jan; 20(1):194-205. PubMed ID: 36458739
[TBL] [Abstract][Full Text] [Related]
20. [Cytochrome P-450 3A4--the most important arena for drug interactions in the body].
Spigset O; Molden E
Tidsskr Nor Laegeforen; 2008 Dec; 128(24):2832-5. PubMed ID: 19092951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
